Amgen, Allergan Launch 2 Biosimilars With Court's Blessing
Amgen and Allergan have started selling their biosimilar versions of Genentech's blockbuster cancer treatments Avastin and Herceptin in the U.S., announcing the launch immediately after a Delaware federal judge refused to...To view the full article, register now.
Already a subscriber? Click here to view full article